Biotricity, Inc. (BTCY)
$0.775101
-0.03 (-4.31%)
Rating:
Recommendation:
-
| Symbol | BTCY |
|---|---|
| Price | $0.775101 |
| Beta | 2.198 |
| Volume Avg. | 0.20M |
| Market Cap | 40.421M |
| Shares () | - |
| 52 Week Range | 0.399-3.35 |
| 1y Target Est | - |
| DCF Unlevered | BTCY DCF -> | |
|---|---|---|
| DCF Levered | BTCY LDCF -> | |
| ROE | -5125.17% | Strong Sell |
| ROA | -143.33% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | -285.20% | Sell |
| P/E | - | |
| P/B | -6.15 | Strong Sell |
Latest BTCY news
About
Download (Excel)Dr. Waqaas Al-Siddiq Ph.D.
Healthcare
Medical Devices
NASDAQ Capital Market
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.